Skip to main content Homepage

Pain Management

Upcoming Pain Management Events

  • MAT Waiver Training
    • Date: Friday, December 17, 2021
    • Time: 8 a.m. - 12:30 p.m. PST
    • Location: Virtual
    • Tuition: No Cost

    For more information, please view the training brochure. Click here to register.

    For details about waiver training requirements and exemptions, please see these FAQs from the Substance Abuse and Mental Health Services Administration (SAMHSA). 

Pain Management Updates

Updated Pain Management CME Course and Resources

The Oregon Pain Management Commission (OPMC) recently launched a new version of “Changing the Conversation About Pain," a CME course that will be required for all Oregon clinicians beginning January 1, 2022. The updated course now includes topics such as health equity and has been expanded from 1.0 to 1.5 CME credit hours.

Additionally, a workgroup comprised of representatives of the OPMC, Oregon Health Authority (OHA) Public Health, and Providence Health & Safety, as well as six clinical experts, have developed the Pain Education Toolkit, which offers patient and provider educational resources on topics such as sleep, nutrition, and medications. Visit to access the toolkit. A clinician-focused version is also available at

ATTENTION: The Oregon Health Authority adopted temporary rules to align with requirements in 42 U.S.C. 1396w-3a. The temporary rules require Oregon Health Plan (OHP) enrolled providers and Coordinated Care Organization (CCO) contracted providers to check the Prescription Drug Monitoring Program (PDMP) before prescribing controlled substances to covered individuals, see OAR 410-120-1260(13) and OAR 410-141-3855(15) for details. 

ATTENTION: CDC Advises Against Misapplication of the Guideline for Prescribing Opioids for Chronic Pain

Authors of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain are advising against misapplication of the guideline that can risk patient health and safety, raising awareness of the following issues:

  • Misapplication of recommendations to populations outside of the Guideline's scope. The Guideline is intended for primary care clinicians treating chronic pain for patients 18 and older. Examples of misapplication include applying the Guideline to patients in active cancer treatment, patients experiencing acute sickle cell crises, or patients experiencing post-surgical pain.
  • Misapplication of the Guideline's dosage recommendation that results in hard limits or “cutting off" opioids. The Guideline states, “When opioids are started, clinicians should prescribe the lowest effective dosage. Clinicians should… avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate dosage to ≥90 MME/day." The recommendation statement does not suggest discontinuation of opioids already prescribed at higher dosages.
  • The Guideline does not support abrupt tapering or sudden discontinuation of opioids. These practices can result in severe opioid withdrawal symptoms including pain and psychological distress, and some patients might seek other sources of opioids. In addition, policies that mandate hard limits conflict with the Guideline's emphasis on individualized assessment of the benefits and risks of opioids given the specific circumstances and unique needs of each patient.
  • Misapplication of the Guideline's dosage recommendation to patients receiving or starting medication-assisted treatment for opioid use disorder. The Guideline's recommendation about dosage applies to use of opioids in the management of chronic pain, not to the use of medication-assisted treatment for opioid use disorder. The Guideline strongly recommends offering medication-assisted treatment for patients with opioid use disorder.

More information about the CDC Guideline for Prescribing Opioids for Chronic Pain and how appropriately apply it to patient care, visit the CDC's website.

ATTENTION: In July 2020, the Food and Drug Administration provided guidance directing health care professionals to discuss naloxone, a potentially life-saving medication that can reverse drug overdoses, with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. See the FDA's website for additional information. 

ATTENTION: All Oregon-licensed physicians and PAs who have a DEA number are required to register for the Prescription Drug Monitoring Program (PDMP). Register at by selecting "Create an Account." For more information, please review OAR 847-010-0120 and OAR 333-023-0825. For questions, contact the PDMP at 866-205-1222 or

Oregon Medical Board Information

Statement of Philosophy: Pain Management
The Material Risk Notice Form

Continuing Education Requirements for Pain Management

Prescription Drug Monitoring Program

Medical Marijuana

Oregon Opioid Prescribing Guidelines

Oregon Opioid Tapering Guidelines
The Oregon Medical Board endorsed these guidelines in January 2020.

Oregon Acute Opioid Prescribing Guidelines

The Oregon Medical Board endorsed these guidelines in January 2019.

Oregon Chronic Opioid Prescribing Guidelines

The Oregon Medical Board endorsed these guidelines in January 2017.

 Oregon Pain Management Commission one-hour pain management CME (required) – The pain education module "Changing the Conversation About Pain: Pain Care is Everyone's Job," and a Pain Care Toolbox are available from the Oregon Health Authority. The module qualifies for up to one AMA PRA Category 1 CreditTM of continuing medical education.  

Additional Resources

The Oregon Pain Guidance website provides pain management guidance and tools for healthcare professionals as well as patients and families.  
The Oregon Prescription Drug Monitoring Program (PDMP) assists healthcare professionals in providing better patient care. 

COPE (Collaborative Opioid Prescribing Education) Course – The University of Washington's free, online, interactive course promotes a shared decision-making approach between providers and patients.

The Federation of State Medical Boards' Opioids and Pain Management webpage offers numerous resources on state, federal, and FSMB opioid policies. 

Note: The National Transportation Safety Board reminds health care providers to discuss with patients the effects that their medical conditions and medications may have on their ability to safely operate a vehicle in any mode of transportation.

Medication Assisted Treatment (MAT) for Opioid Addiction – Physician Assistants and Nurse Practitioners are now included among the healthcare professionals who may provide MAT for opioid addiction. More information is available on the Substance Abuse and Mental Health Services Administration (SAMHSA) website. All MAT providers must complete training and be granted a waiver by the DEA.  The required 24-hour continuing education training is free and available through the Providers' Clinical Support System

SAMHSA began certifying PAs and NPs on February 21, 2017.  As of August 28, 2018, there were 687 certified PAs nationwide and 2,471 certified NPs.  SAMHSA says, "More buprenorphine prescribers are needed to combat the opioid crisis and treat substance use disorders, particularly in rural areas."

Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how